Millions of women suffering the long shadow of endometriosis or complications from childbirth stand to gain from a sweeping new science and technology partnership between Britain and France, unveiled today as Technology Secretary Liz Kendall touched down in Paris for G7 talks.
The agreement, light on diplomatic gloss and heavy on practical intent, places artificial intelligence and shared clinical data at the heart of a joint push into two areas that have long been the Cinderellas of medical research: women’s health and infectious disease. For an SME-rich life sciences sector on both sides of the Channel, it also reopens a more reliable pipeline of cross-border funding, talent and commercial opportunity at a moment when post-Brexit research ties have been quietly knitting back together.
A long-overdue focus on women’s health
Officials say the partnership will accelerate work on conditions that have been systematically under-researched and under-diagnosed, with patients on both sides of the Channel waiting years for answers. By pooling datasets and clinical expertise, British and French researchers expect to deliver earlier diagnoses, safer pregnancies and more personalised care. As the Women’s Organisation has previously warned in Business Matters, more than a third of women feel unsupported on issues such as endometriosis, fertility and menopause, with measurable knock-on effects on productivity, promotion and pay across the SME workforce.
Kendall, who took on the science and technology brief last September, said the deal would “tackle some of the biggest challenges in women’s health, deliver safer and healthier pregnancies, and accelerate the fight against infectious diseases worldwide”. She added that the spirit of cross-Channel co-operation would carry into wider G7 discussions on AI adoption and online child safety.
Superbugs and supercomputers
The agreement also turns the firepower of cutting-edge imaging and AI on infectious diseases, with researchers set to share global data on drug-resistant E. coli, tuberculosis, malaria and emerging viruses. The intention is blunt: faster detection of microbes that shrug off existing treatments, quicker identification of outbreaks, and a sharper clinical edge for the doctors on the front line.
Underpinning the science is a meaningful injection of cash for compute. Nearly £900,000 of UK government funding will deepen ties between the Bristol Centre for Supercomputing, home to the Isambard-AI machine, and France’s national high-performance computing centre, GENCI. Isambard-AI is already crunching workloads from drug discovery to climate modelling, and as Business Matters has reported, Britain’s broader AI compute ambitions are moving fast, with the Stargate UK project set to scale capacity many times over by next year.
A further £300,000 from the UK Treasury, matched by €330,000 from Paris, will fund early-career researcher exchanges via UKRI’s International Science Partnerships Fund, helping junior scientists work in both countries and unlocking joint bids into Horizon Europe.
A more strategic UK–EU axis
Philippe Baptiste, France’s minister for higher education, research and space, framed the agreement as “a decisive step” in the two nations’ scientific partnership, anchored in trust and aimed at “tangible results in artificial intelligence, health, and beyond”. Read alongside the recent UK–EU partnership announced to boost AI adoption and economic growth, it suggests a more strategic, less transactional approach to European research and innovation than has been evident for some years.
For British SMEs in life sciences, diagnostics, femtech and AI tooling, the practical implications are worth watching. A simpler route to joint French projects, cleaner access to Horizon Europe and a fully wired-up supercomputing pipeline lowers the cost of cross-border collaboration and, crucially, the cost of getting product to clinical trial. The UK government’s continued push for closer industrial and research ties with Europe is broadly consistent with the record £55bn long-term R&D commitment Kendall set out earlier this year, a signal that ministers see science partnerships not as nice-to-have diplomacy but as core economic infrastructure.
A separate prize for Imperial
In a parallel piece of choreography, Imperial College London and France’s National Centre for Scientific Research will today sign a separate landmark agreement on metabolism research, targeting heart disease, cancer and neurodegenerative disorders. According to the UK Science and Innovation Network’s France country snapshot, health and emerging technologies are now the two anchor pillars of UK–France scientific co-operation.
The headline numbers, taken alone, are modest by Whitehall standards. The strategic message is not. Britain and France are quietly rebuilding the rails for the kind of cross-Channel science the rest of Europe will find increasingly difficult to ignore, and for the SMEs that ride on them, the rails are getting straighter.